Search
Entrada Therapeutics Inc
TRDAAdd to Watchlist
7.488USD
-0.252-3.25%
Market hours （ET）Quotes delayed by 15 min
286.68MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-26The current earnings forecast score of Entrada Therapeutics Inc is 8.50, ranking 108 out of 387 in the Biotechnology & Medical Research industry. The average price target is 16.50, with a high of 20.00 and a low of 13.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
18.750
Target Price
+142.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Entrada Therapeutics Inc
TRDA
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Entrada Therapeutics Inc's expected revenue for the next quarter?
Entrada Therapeutics Inc's expected revenue is 411.43K.
What is Entrada Therapeutics Inc's price target?
Analysts forecast that Entrada Therapeutics Inc's price target is USD 16.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 13.00.
How have Entrada Therapeutics IncTRDA's recent earnings per share performed?
The market expectation was USD -0.95, while Entrada Therapeutics IncTRDA's earnings per share (EPS) for the previous quarter was USD -0.94. EPS for the next quarter is expected at USD -1.05.
What is the analyst rating for Entrada Therapeutics Inc?
Based on the ratings of Entrada Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
